No Data
No Data
B.Riley Financial Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $92
Robust CMI Drug Sales and Synergistic Commercial Strategies Bolster Buy Rating for Cytokinetics
Express News | Cytokinetics to Announce Second Quarter Results on August 8, 2024
Cytokinetics Insider Sold Shares Worth $416,246, According to a Recent SEC Filing
Express News | Cytokinetics Announces Seven Upcoming Presentations at the European Society of Cardiology Congress 2024
Cytokinetics(CYTK.US) Officer Sells US$624.34K in Common Stock
No Data